NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported that its first-quarter 2013 revenues increased 2 percent year over year led by sales gains for its SAFC business.

The St. Louis-based chemicals and research products firm had total revenues of $675 million for the three months ended March 31, compared to revenues of $665 million for the first quarter of 2012. It beat the consensus Wall Street estimate of $672.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.